Trial Review

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000409572p
Ethics application status
Not yet submitted
Date submitted
14/03/2024
Date registered
4/04/2024
Date last updated
4/04/2024
Date data sharing statement initially provided
4/04/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Prevention of Reperfusion Injury in Myocardial infarction (PRIME) trial
Scientific title
Does Paracetamol decrease reperfusion injury to patients presenting with acute ST-elevation myocardial infarction when given prior to primary percutaneous intervention.
Secondary ID [1] 311736 0
Nil
Universal Trial Number (UTN)
Trial acronym
PRIME
Linked study record

Health condition
Health condition(s) or problem(s) studied:
ST-Elevation Myocardial Infarction 333218 0
Condition category
Condition code
Cardiovascular 329908 329908 0 0
Coronary heart disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Patients presenting with acute ST-Elevation Myocardial Infarction (STEMI) to Waikato Hospital, who will be treated with Primary Percutaneous Coronary Intervention (PCI) with in four hours, will be given 1.5g of Paracetamol oral tablets prior to PCI and then 1g regularly four times a day, for four days afterwards. This will be recorded on the patient hospital drug chart.
Intervention code [1] 328194 0
Treatment: Drugs
Comparator / control treatment
Historical control data from the ANZACS-QI data base to compare to primary and secondary treatment outcomes. The data will be taken from the two year period prior to the start of the trial.
Control group
Historical

Outcomes
Primary outcome [1] 337673 0
Peak troponin level
Timepoint [1] 337673 0
Day 1, 2, 3, 4 post PCI
Secondary outcome [1] 432793 0
Incidence of ventricular arrhythmia
Timepoint [1] 432793 0
Continuous monitoring during the patients stay in hospital of Day 1, 2, 3, 4 post PCI.
Secondary outcome [2] 432794 0
30-day Mortality rate
Timepoint [2] 432794 0
Day 30 post PCI
Secondary outcome [3] 432795 0
left ventricular ejection fraction
Timepoint [3] 432795 0
prior to discharge from hospital

Eligibility
Key inclusion criteria
Patients presenting to Waikato Hospital with acute ST-Elevation Myocardial Infarction (STEMI) on Electrocardiogram (ECG), as interpreted by Emergency Department (ED) or Cardiology Senior Medical Officer (SMO) or Senior Registrar.
The patient will then be discussed with the on-call Cardiac interventionalist, if the best treatment for the patient is judged to be primary percutaneous intervention (PCI) within the next 4 hours, the enrollment process can then be started.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Allergy to Paracetamol
Known liver failure (Child-Pugh class C)
GCS less than 15
Unable to swallow tablets – ie. intubated or too medically unwell to safely swallow tablets.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
3/06/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment outside Australia
Country [1] 26200 0
New Zealand
State/province [1] 26200 0

Funding & Sponsors
Funding source category [1] 316067 0
Hospital
Name [1] 316067 0
Te Whatu Ora Waikato
Country [1] 316067 0
New Zealand
Primary sponsor type
Hospital
Name
Te Whatu Ora Waikato
Address
Country
New Zealand
Secondary sponsor category [1] 318234 0
None
Name [1] 318234 0
Address [1] 318234 0
Country [1] 318234 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 314885 0
Health and Disability Ethics Committee
Ethics committee address [1] 314885 0
Ethics committee country [1] 314885 0
New Zealand
Date submitted for ethics approval [1] 314885 0
30/04/2024
Approval date [1] 314885 0
Ethics approval number [1] 314885 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 133058 0
Dr Adrian Owen
Address 133058 0
Waikato Hospital, 183 Pembroke Street, Hamilton 3204
Country 133058 0
New Zealand
Phone 133058 0
+64221885215
Fax 133058 0
Email 133058 0
[email protected]
Contact person for public queries
Name 133059 0
Adrian Owen
Address 133059 0
Waikato Hospital, 183 Pembroke Street, Hamilton 3204
Country 133059 0
New Zealand
Phone 133059 0
+64221885215
Fax 133059 0
Email 133059 0
[email protected]
Contact person for scientific queries
Name 133060 0
Adrian Owen
Address 133060 0
Waikato Hospital, 183 Pembroke Street, Hamilton 3204
Country 133060 0
New Zealand
Phone 133060 0
+64221885215
Fax 133060 0
Email 133060 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• only researchers who provide a methodologically sound proposal

Conditions for requesting access:
• -

What individual participant data might be shared?
• Individual participant data underlying published results only

What types of analyses could be done with individual participant data?
• meta-analysis

When can requests for individual participant data be made (start and end dates)?
From:
Immediately following publication, no end date

To:
-

Where can requests to access individual participant data be made, or data be obtained directly?
• access subject to approvals by Principal Investigator, [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
21871Study protocol    Study-related document.docx



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.